BioLife Sciences, Inc. (OTC:PK BLFE) (BioLife or the Company) is Pleased to Announce the Release of the Prototype of the Company’s Copper-Infused Microfiber Towels for Q2 of the Fiscal Year

HENDERSON, NV, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – The Copper-Infused Microfiber Towels are copper-variations of traditional microfiber towels, designed to outlast competitors’ standard microfiber towel production anchored to copper’s ability to limit bacteria reproduction.

The Company’s copper-infused prototype will leverage the natural antimicrobial benefits of copper ions, which have been shown to kill 99.99% of harmful bacteria and viruses. Copper ions are proven pathogen killers and have antimicrobial prevention abilities.

Traditional microfiber towels push dust particles from one place to another without ever actually capturing the particles. When used dry, the BioLife Copper-Infused Microfiber Towels are designed to provide an electrostatic charge that attracts even the smallest pieces of dirt, grease and moisture. The copper then reinforces the cleaned area with an antimicrobial shielding, providing long-lasting protection. Copper ions are proven pathogen killers and have documented antimicrobial benefits.

The Microfiber Towels Market is likely to experience worldwide growth of $790.5 million (USD) by 2026 from $685.6 million (USD) in 2020, at an expected CAGR of 2.4% during 2022-2026. Despite this growth, market share concentration remains low, with several large international manufactures competing with many smaller regional and local manufactures.

About BioLife Sciences, Inc.

BioLife Sciences, Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. It’s core business develops, licenses and distributes antimicrobial products and disruptive technologies. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.

Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037

Disclaimer:

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.